

Fig 1A. ScFv library




Fig 1B. ScFv-CBD library




Fig. 2A. HLA-A2/G9-209





Fig. 2B. HLA-A2/G9-280



[illegible]

49	50	51	52	53	54	55	56	57	58	59	60	61	62
GAC	ACA	TCC	AAC	GTG	GCT	CCT	GGA	GTC	CCT	TTT	CGC	TTC	AGT
asp	thr	ser	asn	val	ala	pro	gly	val	pro	phe	arg	phe	ser

FIGURE 3A(ii)


63 64 65 66 67 68 69 70 71 72 73 74 75 76
GGC AGT GGG TCT GGG ACC TCT TAT TCT CTC ACA ATC AAC CGA
gly ser gly ser gly thr ser tyr ser leu thr ile asn arg

77 78 79 80 81 82 83 84 85 86 87 88 89 90
ATG GAG GCT GAG GAT GCT GCC ACT TAT TAC TGC CAG GAG TGG
met glu ala glu asp ala ala thr tyr tyr cys gln glu trp

91 92 93 94 95 96 97 98 99 100 101 102 103
AGT GGT TAT CCG TAC ACG TTC GGA GGG GGG ACA AAG TTG
ser gly tyr pro tyr thr phe gly gly gly thr lys leu

20250120 10:20:00

Fig. 3B
20ET20" PDEE 209T 3C






Fig. 4

2007-07-20 10:00:00

Fig. 5A








Fig. 5B



Protein synthesis (% of control)




Fig. 7A




Fig. 7B




Fig. 7C